Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing, and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated hair growth product
(“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), is excited
to announce that it will be a Marquee Sponsor for Barstool Sports’
week-long programming schedule surrounding the Big Game in Las
Vegas on Sunday, Feb 11, 2024.
The MangoRx brand will be featured across
Barstool programming during the week of the Super Bowl, including
The Dozen Trivia Live Show Pro-Am with Dave Portnoy and other
Barstool fan favorites, Stool Scenes' "Super Bowl Special", and The
Rundown, in addition to sponsoring the Big Game’s Day-of livestream
from Chicago HQ, the brand’s content house in Las Vegas, and
several other podcasts and radio shows.
In addition, as a Marquee Sponsor, MangoRx will
be prominently featured on the Barstool Podcasts starting the week
of January 22nd and running through March 15th with an estimated
number of over 7 million views and impressions.
Dave Portnoy, one of the most recognizable faces
in the American sports media industry, founded Barstool Sports,
growing the brand into the multi-million-dollar preeminent digital
sports media presence. Portnoy, famously known as “El Presidente”,
aka “The Mogul”, aka “Davey Pageviews” and the “King of Pizza
Reviews”, has established an unassailable empire of influence
through Barstool Sports' deeply authentic voice. Already the #1
most followed publisher in the 18-34 demographic and a top-ten
global podcast publisher and set to become the first brand to
achieve 7 billion likes on TikTok, the fastest growing social media
platform worldwide, Barstool Sports, through its innovative
content, has established a massive distribution footprint on
multiple platforms.
"The Barstool livestream for the Big Game saw
its audience grow by nearly 200% year-over-year from 2022 to 2023,"
remarked Jacob Cohen, CEO and Co-Founder of MangoRx. “This is dead
center in terms of our target market for our major products, and we
couldn’t find a bigger megaphone to power our brand reach than
Dave’s empire of influence. Barstool is #1 across the board and we
are thrilled to align our brand with Dave and his team for the
biggest media event of the year!”
As a Marquee sponsor of Barstool’s Big Game live
stream, MangoRx’s products and branding will be present throughout
their newly opened Chicago HQ including live promotional giveaways
to viewers of the stream.
“We’re thrilled to continue and build upon our
partnership with MangoRx in what has been a natural fit between
both of our brands”, said Ryan McDermott, Head of Sales, Barstool
Sports. “The Big Game is the biggest night for advertisers and
we’re looking forward to showcase ‘Prime’ to our passionate fans so
this product stands out all week long.”
MangoRx will be using this marketing opportunity
to feature its newly launched product, 'Prime' by MangoRx, powered
by KYZATREX®️, an innovative FDA-approved oral Testosterone
Replacement Therapy (TRT) product KYZATREX, a prescription drug
that is used to treat adult men who have low or no testosterone
levels due to certain medical conditions, is one of only three FDA
approved TRT treatments that is delivered orally--as opposed to the
traditional, invasive, and inconvenient injection-based drug
delivery protocol. KYZATREX delivers testosterone in a softgel
capsule that is absorbed primarily via the lymphatic system,
avoiding liver toxicity.
KYZATREX is one of the only FDA approved
testosterone replacement therapy ("TRT") treatments that is
delivered orally—as opposed to the traditional, invasive, and
inconvenient injection-based drug delivery protocol. KYZATREX is
delivered as a softgel capsule that is absorbed primarily via the
lymphatic system, avoiding liver toxicity.
The benefits of ‘Prime,’ powered by KYZATREX,
over traditional injectable TRTs include enhanced vitality,
improved mood, sharper cognition, optimized physical performance,
and balanced hormonal levels at 96% efficacy by day 90, as
demonstrated in Phase 3 clinical research by Marius
Pharmaceuticals. With ‘Prime,’ MangoRx will expand broad-based
consumer access to this revolutionary therapy.
About Barstool Sports
Barstool Sports is one of the most influential
lifestyle brands in America. Founded by Dave Portnoy in 2003 who
over the years has become a media mogul today known to many as the
King of the Internet, the famous @stoolpresidente on Instagram, X
(formerly Twitter), Facebook, Tik Tok, YouTube & founder of the
popular One Bite Pizza Reviews across the U.S.
Barstool Sports began as a four-page sports
newspaper that he distributed by hand on Boston's subway platforms
and street corners. With a rich 21-year history, Over the years,
under Dave Portnoy's guidance, Barstool Sports transformed into a
multimedia empire that includes podcasts, video content, and
merchandise.
Barstool Sports has one of the most highly
coveted, fiercely loyal, and incredibly engaged audiences, which
has put Barstool at the top of the charts. Barstool Sports is the
preeminent digital sports media brand that has established an
extremely influential and deeply authentic voice. Barstool Sports
creates innovative content with massive distribution on multiple
platforms, including web, apps, podcasts, radio, video, social,
events, pay-per-view, subscription, and TV to an incredibly engaged
audience. Barstool Sports reaches a hyper-engaged audience of 66+
million monthly unique users, with 46% of men and women in the
coveted 18-34 age demographic. Barstool steals the spotlight in
cultural moments. Their presence at major sporting events drives
more awareness, engagement, and viewership in younger demographics
than any other media brand. Barstool Sports and its founder, Dave
Portnoy, consistently ranks as the #1 most influential social media
account at major sporting events like the Kentucky Derby, Super
Bowl, PGA Championship, U.S. Open Golf, Stanley Cup Finals,
NASCAR's Daytona 500, and more.
About MangoRx
MangoRx is focused on developing a variety of
men's health and wellness products and services via a secure
telemedicine platform. To date, the Company has identified men's
wellness telemedicine services and products as a growing sector and
especially related to the area of erectile dysfunction (ED) and
hair growth. Interested consumers can use MangoRx’s telemedicine
platform for a smooth medical prescription that is exclusively
compounded for each individual. Orders will then be reviewed by a
physician and, if approved, fulfilled and discreetly shipped
through MangoRx’s partner compounding pharmacy and right to the
patient’s doorstep.
To learn more about MangoRx’s mission and other
products, please visit www.MangoRx.com or on social media
@Mango.Rx.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen and President, Jonathan Arango, combined have majority voting
control over the Company; risks related to the significant number
of shares in the public float, our share volume, the effect of
sales of a significant number of shares in the marketplace, and the
fact that the majority of our shareholders paid less for their
shares than the public offering price of our common stock in our
recent initial public offering; the fact that we have a significant
number of outstanding warrants to purchase shares of common stock
at $1.00 per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties. More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended June 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on
social media: https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficialOr just click here
to see why Orange is the new Blue:
https://www.mangorx.com
FOR PUBLIC RELATIONS Lucky
Break Public Relations Sahra Simpson Sahra@luckybreakpr.com (323)
602-0091 ext. 704
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations Email: investors@mangorx.com
MEDIA CONTACT PHOENIX MGMT
Marketing & Consulting info@phoenix-mediamarketing.com
SOURCE:
Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Jul 2024 to Jul 2024
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Jul 2023 to Jul 2024